내용 바로 가기

종양학과

지혈 관리 및 최적화

항섬유소용해제

Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (새로운 창 열기)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Source‎: Cancer 2013;119(21):3784-7.

Indexed‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (새로운 창 열기)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (새로운 창 열기)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Source‎: Lancet 1989;334(8655):122-4.

Indexed‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (새로운 창 열기)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (새로운 창 열기)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Source‎: Cancer 2006;107(1):136-40.

Indexed‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (새로운 창 열기)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (새로운 창 열기)

Marshall A, Li A, Drucker A, Dzik W.

Source‎: Hematol Oncol 2016;34(3):147-53.

Indexed‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (새로운 창 열기)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (새로운 창 열기)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Source‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indexed‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (새로운 창 열기)

재조합활성응고인자 VII (rFVIIa)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (새로운 창 열기)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Source‎: Am J Hematol 2006;81(9):720.

Indexed‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (새로운 창 열기)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (새로운 창 열기)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Source‎: Am J Hematol 2002;69(3):219-22.

Indexed‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (새로운 창 열기)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (새로운 창 열기)

Hsieh A, Cheong I.

Source‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Indexed‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (새로운 창 열기)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (새로운 창 열기)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Source‎: Haemostasis 1996;26 Suppl 1:159-64.

Indexed‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (새로운 창 열기)

응고인자농축물(Coagulation Factor Concentrates)

Management of bleeding complications of hematologic malignancies. (새로운 창 열기)

Green D.

Source‎: Semin Thromb Hemost 2007;33(4):427-34.

Indexed‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (새로운 창 열기)

Management of bleeding in patients with advanced cancer. (새로운 창 열기)

Pereira J, Phan T.

Source‎: Oncologist 2004;9(5):561-70.

Indexed‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (새로운 창 열기)

데스모프레신